Tumor‐Bearing Status Accelerates Bleomycin‐Induced Pulmonary Inflammation via Endothelial Activation
Open Access
- 30 March 2026
- journal article
- Published by Wiley in Thoracic Cancer
- Vol. 17 (7) , e70272
Abstract
Background: Drug‐induced lung disease (DILD) is a severe adverse event of cancer treatment. Several clinical reports have demonstrated an association between DILD and tumor progression. However, the underlying mechanism remains unclear. This study aimed to elucidate the role of tumor‐bearing status in the development of DILD. Methods: We prepared a subcutaneous Lewis lung carcinoma (LLC) and KLN205‐bearing model. To trigger DILD, bleomycin (BLM) was administered subcutaneously. mRNA expression associated with endothelial activation (PAI‐1, vWF, and ICAM‐1), inflammatory cell infiltration, and alveolar wall thickness was assessed by using bronchioalveolar lavage fluid (BALF) and lung tissue. Additionally, the role of high‐mobility group box 1 (HMGB1) in tumor‐bearing status was examined. Results: Compared with control mice, LLC‐ and KLN205‐bearing mice showed a tendency toward increased expression of at least one of PAI‐1, vWF, and ICAM‐1 on endothelium, along with inflammatory cell infiltration in the lungs. BLM‐treated mice with LLC showed more inflammatory cell infiltration than BLM‐treated mice, accompanied by a significant increase in PAI‐1, vWF, and ICAM‐1 expression on endothelium. Moreover, BLM‐treated mice with LLC exhibited pronounced alveolar wall thickening. In LLC‐bearing mice, serum HMGB1 levels were significantly higher compared with control mice. Additionally, inflammatory cell infiltration in the lungs tended to be increased by the intraperitoneal injection of HMGB1, which was accompanied by increased expression of vWF and ICAM‐1 on endothelium. Conclusions: This study showed that tumor‐bearing status elicits proinflammatory activation in endothelial cells and inflammatory cell infiltration into the lungs that aggravates DILD caused by BLM.Keywords
Funding Information
- Japan Society for the Promotion of Science (18K15951)
- Japan Society for the Promotion of Science (22K16194)
This publication has 30 references indexed in Scilit:
- Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapyInternational Journal of Clinical Oncology, 2022
- The mechanism of HMGB1 secretion and releaseExperimental & Molecular Medicine, 2022
- Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatmentESMO Open, 2022
- Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung diseaseRespiratory Medicine, 2020
- Pulmonary Toxicities from Conventional ChemotherapyClinics in Chest Medicine, 2017
- Consensus statement for the diagnosis and treatment of drug-induced lung injuriesRespiratory Investigation, 2013
- HMGB1 induces an inflammatory response in endothelial cells via the RAGE-dependent endoplasmic reticulum stress pathwayBiochemical and Biophysical Research Communications, 2013
- The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathwayMolecular and Cellular Biochemistry, 2013
- Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancerRespiratory Medicine, 2009
- Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancersLaboratory Investigation, 2009